Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Program Description

Anemia is a common complication of myeloid disorders such as myelofibrosis (MF) and myelodysplastic syndromes (MDS) that can lead to fatigue, increased need for red blood cell transfusions, and iron overload. Oncology pharmacists play a vital role in delivering effective management strategies to resolve anemia in myeloid disorders, particularly through the use of novel therapies. This program will delve into the multifaceted causes and consequences of anemia in MDS and MF, including the burden of transfusion-dependent anemia. The treatment landscape for anemia in myeloid disorders is rapidly expanding, and the discussion will explore the historical challenges of anemia management as well as emerging therapeutic strategies and related mechanisms of action, efficacy data from key clinical trials, and the current role of emerging therapies in the treatment paradigm. Oncology pharmacists will review practical guidance on supportive care, dose adjustments, and toxicity management for these emerging therapies to optimize anemia management.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: September 22, 2025
Expiration date: September 22, 2026

Time to complete activity: 1.0 hours

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Identify the key mechanisms underlying anemia in myelofibrosis (MF) and myelodysplastic syndromes (MDS) to strengthen pharmacists' understanding of emerging therapeutic strategies
2. Explore the clinical applications of novel therapies for anemia in MF and MDS, focusing on how these strategies enhance patient care and outcomes compared with historical approaches
3. Employ appropriate dose adjustments and supportive care measures to enhance treatment outcomes for anemia in myeloid disorders

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-304-H01-P. The activity is available for CE credit through September 22, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Anthony Perissinotti, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Abbvie, Servier, Syndax, Amgen

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Amy L. Morris, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms